CORAL GABLES, FL / ACCESSWIRE / March 12, 2019 / The healthcare stock market is comprised of innovative companies working diligently to design, manufacture, and commercialize state-of-the-art tech-driven solutions for the healthcare industry. As we've seen in recent years, companies are testing out new technologies to give patients the quality of care that they both need, as well as deserve. We've seen developments in telemedicine, augmented reality, and data analytics, all for the purpose of taking the healthcare sector into the future. It is the responsibility of healthcare companies to meet the oncoming challenges presented by infectious diseases and ailments, and so long as they can meet these requirements, the healthcare sector could generate market excitement. Premier Health Group (OTC: PHGRF) (CSE: PHGI), ENDRA Life Sciences Inc (NDRA), Novavax Inc (NASDAQ: NVAX), and Aevi Genomic Medicine Inc (NASDAQ: GNMX) are 4 healthcare companies raising the bar on Tuesday.
Premier Health Group (OTC: PHGRF) (CSE: PHGI) is a company determined to develop innovative approaches that combine human skill-based expertise with state-of-the-art technologies to offer to their patients the best possible treatment solutions and primary care. At a time where consumers depend on healthcare companies to provide qualitative care solutions, Premier Health is prepared to meet the needs of its patients.
Premier Health Group (OTC: PHGRF) (CSE: PHGI) announced earlier this month that the Company will be working with NexTech AR solutions to explore bringing augmented reality technology to its patient-centric healthcare app. Utilizing AR as a learning tool in training healthcare professionals creates a highly engaging and immersive educational experience which aids in retention and how well complex concepts can be grasped.
Following the announcement, Dr. Essam Hamza, CEO of Premier Health Group (OTC: PHGRF) (CSE: PHGI), commented, "at Premier Health we pride ourselves in being at the forefront of changes in healthcare, so we are thrilled to be a part of the future of healthcare by enabling state of the art technological advancements to our patient-centric telemedicine app. AR has the potential to revolutionize both the access to data and the delivery of healthcare."
For More Information On Premier Health Group, Click Here
ENDRA Life Sciences Inc (NDRA), a developer of enhanced ultrasound technologies, reported its financial and operational results for the full year ended December 31, 2018, yesterday. Over the course of 2018, the Company received approval from Health Canada for an Investigational Testing Authorization to commence a first human feasibility study with ENDRA's TAEUS reference system targeting Non-Alcoholic Fatty Liver Disease, as well as renewed and extended terms of global collaboration agreement with GE Healthcare to accelerate development of ENDRA's Thermo-Acoustic Enhanced UltraSound clinical platform.
Francois Michelon, CEO of ENDRA, said, "we renewed our partnership with GE Healthcare for an additional two years and grew our IP portfolio from 33 to 41 assets. We also initiated our first-in-human study, strengthened our balance sheet and implemented a quality management system supporting CE regulatory approval and strongly positioning ENDRA for a controlled European launch in 2019."
For More Information On ENDRA Life Sciences Inc, Click Here
Novavax Inc (NVAX), a late-stage biotechnology company determined to improve global health through the discovery, development, and commercialization of innovative vaccines, saw impressive gains in the market on Tuesday, with shares up 3.43%, trading at $0.52 per share. Earlier this week, the Company announced that it will report its fourth quarter and year-end financial and operating results following the close of the U.S. financial market on Monday, March 18, 2019.
For More Information On Novavax Inc, Click Here
Aevi Genomic Medicine Inc (GNMX) announced in early January that the ASCEND trial, a genomically-guided Phase 2 double-blind, placebo-controlled clinical trial of orally-administered AEVI-001 (100 - 400 mg BID) in children aged 6 - 17 with Attention Deficit Hyperactivity Disorder (ADHD) with an mGluR copy number variant (Part A) or without an mGluR copy number variant (Part B), did not achieve statistical significance on the primary endpoint of reduction of ADHD-RS in either Part A or Part B after 6 weeks of treatment with AEVI-001.
Following the announcement, Michael F. Cola, CEO of Aevi Genomic, said, "we plan to conduct a full review of the data with our scientific advisers in the coming days and consider our options. We want to thank the investigators, study coordinators and the entire Aevi team for their hard work on this innovative study. We also especially want to thank the patients and their families for their participation. We remain committed to our mission of bringing novel targeted therapies to children with the serious rare and orphan disease."
For More Information on Aevi Genomic Medicine Inc, Click Here
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.
Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 CASH for & were paid "500,000" shares of restricted common shares (as of 1/2/2019). Midam has been compensated an additional $100,000 by Premier Health Group to extend the period of coverage to June 1, 2019. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.
Contact Information:
SOURCE: StockPrice.com